ocular and cognitive abnormalities

A small-molecule compound counteracts some of the effects of abnormal genetic instructions in MMD1

posted on November 3, 2009 - 10:00pm
  A compound that has the potential to be refined and modified into a treatment for type 1 myotonic dystrophy (MMD1, or DM1) has been identified by researchers at the University of Oregon in Eugene, and the University of Rochester (N.Y.) School of Medicine and Dentistry.

New content is being added every day. Please check back again.